Advanced Biliary Tract Carcinoma Clinical Trial
Official title:
A Phase I/II Study of First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
The purpose of this study is to test an investigational combination of drugs for bile duct or gallbladder cancers. Gemcitabine and cisplatin are two forms of chemotherapy commonly used in combination to treat bile duct and gallbladder cancers. The investigators are looking to improve treatment results. They will attempt to do so by adding the drug MEK162 to the treatment plan. MEK162 acts by blocking a protein called MEK 1/2 which helps cancer cells grow and divide. This study will help answer the question of whether MEK162 is a helpful drug in patients with bile duct or gallbladder cancers when given with gemcitabine and cisplatin.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05451290 -
Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03704480 -
Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.
|
Phase 2 | |
| Recruiting |
NCT05733000 -
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT04550624 -
Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05969860 -
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
|
Phase 2 | |
| Completed |
NCT03092895 -
A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC
|
Phase 2 |